Teva agrees SPA for third Phase III MS laquinimod trial
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and Active Biotech are to going ahead with a third Phase III trial of the oral multiple sclerosis drug candidate, laquinimod, after reaching written agreement with the US FDA on a special protocol assessment (SPA).